Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
Earnings: -$53 million in Q4 vs. -$105 million in the same period last year. EPS: -$0.08 in Q4 vs. -$0.15 in the same period last year. Excluding items, Dow Inc. reported adjusted earnings of $2 ...